A new AI-driven drug candidate, rentosertib, has demonstrated potential for biological age reversal in a phase 2a clinical trial, according to recent findings.
The study, which utilized six proteomic aging clocks, suggests the drug could slow down the aging process by at least three years in treated subjects.
Researchers are now planning larger clinical trials to validate these results and assess the long-term safety and efficacy of the AI-generated treatment.